sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Basic information
- Product Name:
- sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
- Synonyms:
-
- sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
- Beraprost sodium (Relative stereochemistry)
- Beraprost Impurity 10 Sodium Salt
- Beraprost impurity 27
- Beraprost Sodium (Mixture of Diastereomers)
- CAS:
- 496807-11-5
- MF:
- C24H31NaO5
- MW:
- 422.5
- Mol File:
- 496807-11-5.mol
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- DMSO: 250 mg/mL (594.57 mM)
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Usage And Synthesis
Biological Activity
Beraprost sodium, a prostacyclin analog, is a stable and orally active PGI2 prodrug. It is an effective vasodilator, which has the potential to study pulmonary hypertension by dilating renal blood vessels and improving microcirculation.
in vitro
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
< /b>
in vivo
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis .
| Animal Model: | 6-8-week-old C57Bl/6J Male Mice |
| Dosage: | 0.6 mg/kg |
| Administration: | Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days |
| Result: < /td> | Mitigated the development of renal interstitial fibrosis. |
target
prodrug of PGI2; Vasodilator
storage
Store at -20°C
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoateSupplier
- Tel
- 021-021-33632979 15002134094
- marketing@targetmol.com
- Tel
- 021-64609169 18901607656
- greensnown@163.com
- Tel
- 020-61855200 13326451905
- 2881290884@qq.com
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Tel
- 18818260767
- sales@chemegen.com